Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talaporfin sodium + FOLFIRI
- Development stage
- Preclinical
- Lead developer
- Meiji Seika Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
talaporfin sodium + FOLFIRI is a drug combination strategy under investigation, primarily for advanced gastrointestinal cancer indications. Talaporfin sodium is a photosensitizer used in photodynamic therapy (PDT) that, upon activation by specific light wavelengths, generates reactive oxygen species leading to cancer cell death. FOLFIRI is a standard intravenous chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU, an antimetabolite DNA synthesis inhibitor), and irinotecan (a topoisomerase I inhibitor)[1][3][5]. This pairing may combine photodynamic therapy's local cell killing by talaporfin sodium with the systemic cytotoxicity of FOLFIRI to enhance tumor control.
- Brand names
- talaporfin sodium + FOLFIRI
- Other names
- talaporfin sodium + FOLFIRI
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on talaporfin sodium + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talaporfin sodium + FOLFIRI.